022 24172311
Sections
Search
DealCurry
Equity
Venture Capital
Private Equity
M&A

Banner
DataBoard Demo
Mergers & Acquisitions | 24 March 2015

Bain Capital Backed Emcure To Buy Brands From Sun-Ranbaxy

by Vivek Singh
Bain Capital Backed Emcure To Buy Brands From Sun-Ranbaxy
Share on Social Media Email Facebook Twitter Linkedin
 
@vivek

Following the directives of CCI to do away with seven brands so as to approve the deal, Sun Pharma and Ranbaxy are selling the seven brands to Bain Capital backed Emcure Pharma. The financial details of the deal remain undisclosed.

While Sun is divesting all products containing Tamsulosin+Tolterodine currently marketed and supplied under the Tamlet brand name, Ranbaxy is selling all products marketed and supplied under the brand names of Eligard, Terlibax, Rosuvas EZ, Olanex F, Raciper L and Triolvance.

In case of Rosuvas EZ, Olanex F and Raciper L, instead of sale, Sun-Pharma would license these brands exclusively, perpetually, irrevocably and on a royalty free basis with the right to sub-license, to Emcure.

It had also received the requisite approval from RBI, High Court of Punjab and Haryana and the US Federal Trade Commission (FTC).

With this it has also crossed all the regulatory approval to create world’s fifth-biggest generics drug maker with operations across 65 countries, 47 manufacturing facilities in five continents and a global portfolio of specialty and generic products.

PwC was the monitoring agency for the divestment process. Khaitan and Co was the legal advisor to Sun on this deal.

PremjiInvest Leads Series C In Mobile OS Developer Cyanogen Inc

PremjiInvest Leads Series C In Mobile OS Developer Cyanogen Inc

PremjiInvest, the family office of country’s third richest man and Wipro’s Chairman – Azim Premji, has led an investment round worth $80 Mn in Cyanogen Inc, a US based startup that seeks to take on Google and Apple providing the world with a new OS like Android but minus the Google.

Read More...

UTI Ventures Divests its Shares in Ascent Capital

UTI Ventures Divests its Shares in Ascent Capital

UTI Ventures Funds Management Company Private Limited, the private equity investment subsidiary of UTI Asset Management Co Pvt Ltd, has sold its stake in Ascent Capital Pvt Ltd to the management of the firm, which is headed by Raja Kumar.

Read More...
Subscribe
Enter your Email address
to receive all the news